Skip to content

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.4×+0.1×
CTO
Citius Oncology, Inc.CTOR
0.5×+0.1×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
6.5×+1.3×
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
19.8×+14.9×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
6.7×+4.4×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
7.7×-14.9×

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×

Where this comes from

Calculated from TuHURA Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s current ratio?
TuHURA Biosciences, Inc. (HURA) reported current ratio of 1.2× in Q1 2026.
How has TuHURA Biosciences, Inc.'s current ratio changed year-over-year?
TuHURA Biosciences, Inc.'s current ratio decreased by 61.6% year-over-year, from 3× to 1.2×.
What is the long-term trend for TuHURA Biosciences, Inc.'s current ratio?
Over 3 years (2022 to 2025), TuHURA Biosciences, Inc.'s current ratio has grown at a -34.9% compound annual growth rate (CAGR), from 2.8× to 0.8×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.